Exec Chat: Signifier Medical Investing In ‘Daytime-Only Treatments’ And Diagnostics For Sleep Apnea
Executive Summary
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
You may also be interested in...
Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.
Using Digital Tools To Unpick The Adherence Problem
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.
In A First, FDA Approves Radioembolization Treatment For Liver Cancer In US
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.